Steven Grekin, DO
Dermatology · Warren, MINPI 1407836877
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Amgen at 29.3% of the total. Reporting peaked in 2019 at $18,783 and has fallen 87.7% since, to $2,320 in 2025. Among dermatology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 937 payments — averaging $51.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$14K
- Almirall LLC$12K
- Incyte Corporation$3K
- AbbVie$2K
- Novartis$2K
- EPI Health, LLC$2K
- plus $13K from 36 others
Across 70 payments — averaging $2168.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$41K
- Journey Medical Corporation$20K
- Avita Medical Americas, LLC$19K
- Takeda Pharmaceuticals U.S.A., Inc.$15K
- Sanofi US Services Inc.$12K
- Aclaris Therapeutics, Inc.$10K
- plus $34K from 7 others
What the payments were for
- Consulting fees$5,61512%
- Speaking & faculty fees$24,95052%
- Travel & lodging$1220%
- Food & beverage$16,91935%
- Education$6731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$13,990
- Seysara$10,339
- Cloderm$1,922
- Rhofade$1,922
- Sitavig$1,800
- Minolira 105mg$1,800
- Minolira 135mg$1,800
- Klisyri$1,200
- COSENTYX$1,200
- VTAMA$384
- NEMLUVIO$262
- MINOLIRA EXTENDED RELEASE$245
- Skyrizi$239
- BOTOX$136
- ZORYVE$127
- Bimzelx$125
- LIBTAYO$124
- BOTOX COSMETIC$123
- BRYHALI$122
- WYNZORA$122
How this compares
$48,279 in reported general payments places this provider in the 90th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 22 | $297,044 |
| Skyrizi PenRisankizumab-Rzaa | 14 | $296,367 |
| OtezlaApremilast | 54 | $260,827 |
| Dupixent SyringeDupilumab | 61 | $227,710 |
| Taltz AutoinjectorIxekizumab | 21 | $163,972 |
| Dupixent PenDupilumab | 44 | $163,837 |
| RinvoqUpadacitinib | 22 | $134,335 |
| SotyktuDeucravacitinib | 15 | $94,521 |
| Humira(Cf) PenAdalimumab | 13 | $86,697 |
| Gentamicin Sulfate | 156 | $6,169 |
| Ketoconazole | 341 | $6,042 |
| Fluticasone Propionate | 282 | $5,782 |
| Tacrolimus | 49 | $4,348 |
| Mometasone Furoate | 177 | $3,241 |
| Ammonium Lactate | 201 | $3,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,563 | $297,04422 claims |
| AmgenOtezla | $14,170 | $260,82754 claims |
| AbbVieRinvoq | $2,495 | $134,33522 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $608 | $94,52115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 dermatology providers in Michigan.
Other dermatology in Warren
- David AltmanWarren$1.9M
- Jeremy GrekinWarren$17K
- Linda Stein GoldWest Bloomfield$3.3M
- Kristi HawleyCaledonia$2.2M
- Michael SiegelWaterford$708K
- Johann GudjonssonAnn Arbor$535K
- Michael DormanWest Bloomfield$433K
- Steven DaveluyDearborn$350K
- Benjamin WorkmanMidland$284K
- Diana WestgateKalamazoo$252K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.